Global Hemolytic Anemia Market, By Treatment Type (Blood Transfusions, Medicines, Plasmapheresis, Surgery, Blood and Marrow Stem Cell Transplants, and Others), Route of Administration (Oral, Parenteral, and Others), Diagnosis (Blood Tests, Biopsy, Urine Tests, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
Hemolytic Anemia Market Analysis and Size
The market is expected to witness steady growth in the coming years, driven by factors such as the increasing prevalence of hemolytic anemia, growing awareness about the disease, and advancements in diagnostic technologies. The market is also likely to benefit from the rising healthcare expenditure in both developed and developing regions, which enables better access to diagnosis and treatment. In addition, developing novel therapies and drugs for managing hemolytic anemia is anticipated to boost market growth further.
The global hemolytic anemia market size was valued at USD 343.47 million in 2023 and is projected to reach USD 523.13 million by 2031, with a CAGR of 5.40% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Blood Transfusions, Medicines, Plasmapheresis, Surgery, Blood and Marrow Stem Cell Transplants, and Others), Route of Administration (Oral, Parenteral, and Others), Diagnosis (Blood Tests, Biopsy, Urine Tests, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), and Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Hemolytic anemia is a medical condition characterized by prematurely destroying red blood cells (RBCs) in the body. This can occur either within the blood vessels (intravascular hemolysis) or in organs such as the spleen or liver (extravascular hemolysis). Hemolysis, or the breakdown of red blood cells, can lead to various symptoms, including fatigue, jaundice (yellowing of the skin and eyes), pale skin, dark urine, and shortness of breath.
Hemolytic Anemia Market Dynamics
Drivers
- Increasing Prevalence of Hemolytic Anemia
The rising prevalence of hemolytic anemia globally can be attributed to various factors, including genetic predisposition, autoimmune disorders, and infections. Genetic factors play a crucial role in developing hemolytic anemia, with certain genetic mutations predisposing individuals to the condition. In addition, autoimmune disorders, where the immune system mistakenly attacks healthy red blood cells, can lead to hemolytic anemia. Infections, particularly those that affect the red blood cells directly or trigger an immune response that targets these cells, are also linked to the development of hemolytic anemia. As the prevalence of these risk factors continues to rise, the overall burden of hemolytic anemia is expected to increase, driving the demand for diagnostic and treatment options in the market.
- Advancements in Diagnostic Technologies
Molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have revolutionized the field of hemolytic anemia diagnosis by enabling the detection of genetic mutations associated with the condition. These methods enable the timely and precise identification of hemolytic anemia, which is crucial for efficiently managing and treating the condition. Biomarker testing is another advancement that has improved the diagnosis of hemolytic anemia by identifying specific markers in the blood that indicate the presence of the condition. These advancements have improved diagnostic accuracy and enabled healthcare professionals to tailor treatment plans to individual patients, leading to better outcomes and driving market growth.
Opportunities
- Growing Awareness and Healthcare Infrastructure
As awareness levels rise, more cases of hemolytic anemia are likely to be diagnosed early, leading to increased demand for diagnostic tests and treatments. In addition, expanding healthcare infrastructure, particularly in developing regions, is expected to drive market growth. Improved access to healthcare facilities and services in these regions will enable more patients to seek diagnosis and treatment for hemolytic anemia, expanding the market size. The growing awareness about hemolytic anemia among healthcare professionals and patients presents a significant market opportunity.
- Rising Healthcare Expenditure
As healthcare expenditure rises, more resources are allocated towards improving healthcare infrastructure, increasing access to healthcare services, and enhancing diagnostic and treatment capabilities. This is expected to result in more hemolytic anemia cases being identified and managed, while also stimulating innovation in diagnostic and therapeutic technologies. Moreover, as healthcare systems become more advanced and efficient, the overall quality of care for hemolytic anemia patients is expected to improve, further driving market growth.
Restraints/Challenges
- Side Effects Associated with Treatment
Immunosuppressive therapies can be effective in managing the condition, but they often come with risks of adverse effects, including increased susceptibility to infections and other immune-related complications. These side effects can limit the use of these therapies and impact market growth. These side effects associated with certain treatments for hemolytic anemia, such as immunosuppressive therapies, present a significant challenge.
- Limited Availability of Effective Therapies
Insufficient access to effective treatments impacts patient outcomes and spurs the search for novel and innovative treatment alternatives. Patients in different regions may face difficulties in accessing appropriate therapies, leading to suboptimal management of their condition. The lack of effective treatments also creates a gap in the market and poses a significant challenge to market growth.
This hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Hemolytic Anemia Market Scope
The market is segmented on the basis of treatment type, route of administration, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Blood Transfusions
- Medicines
- Corticosteroids
- Others
- Plasmapheresis
- Surgery
- Blood and Marrow Stem Cell Transplants
- Others
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Blood Tests
- Biopsy
- Urine Tests
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hemolytic Anemia Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, treatment type, route of administration, diagnosis, end-users, and distribution channel as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the market due to its well-established healthcare infrastructure. Moreover, the increasing emphasis of major key players on innovative technology and the continuous introduction and approval of new products further contribute to regional growth.
Asia-Pacific is expected to witness significant growth during the forecast period due to its large population and increasing healthcare expenditure, along with the availability of effective treatment options at comparatively lower prices than those offered by Western manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hemolytic anemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Hemolytic Anemia Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Fresenius SE & Co. KGaA (Germany)
- Lupin (India)
- ViforPharma Ltd. (Switzerland)
- AMAG Pharmaceuticals (U.S.)
- Akebia Therapeutics, INC. (U.S.)
- CHO-A Pharmaceutical CO., LTD. (South Korea)
- Orion Corporation (Finland)
- Pharmacosmos A/S (Denmark)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
- Zydus Cadila (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-